RECRUITING

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Talk to us

Conditions

Multiple MyelomaRelapsed or Refractory Multiple MyelomaBMS-986393CAR T Cell TherapyRRMMArlocabtagene Autoleucel

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Official Title

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Quick Facts

Study Start:2024-03-21
Study Completion:2032-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06297226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35294-3300
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
UCLA Hematology/Oncology - Westwood (Building 200 Suite 214)
Los Angeles, California, 90095
United States
UCSF Helen Diller Medical Center at Parnassus Heights
San Francisco, California, 94143
United States
Colorado Blood Cancer Institute
Denver, Colorado, 80218
United States
Local Institution - 0062
Jacksonville, Florida, 32224
United States
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176
United States
Moffitt Cancer Center
Tampa, Florida, 33612
United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322
United States
Northside Hospital
Atlanta, Georgia, 30342
United States
Northwestern Memorial Hospital
Chicago, Illinois, 60611
United States
University of Chicago Medical Center
Chicago, Illinois, 60637
United States
University of Iowa
Iowa City, Iowa, 52242
United States
The University of Kansas Cancer Center - Westwood
Westwood, Kansas, 66205
United States
Norton Women's and Children's Hospital
Saint Matthews, Kentucky, 40207
United States
Local Institution - 0065
Baltimore, Maryland, 21218
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Local Institution - 0033
Rochester, Minnesota, 55905
United States
Washington University School of Medicine
Saint Louis, Missouri, 63110
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263
United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
University of North Carolina Medical Center
Chapel Hill, North Carolina, 27599
United States
Local Institution - 0067
Charlotte, North Carolina, 28204
United States
Oncology Hematology Care
Cincinnati, Ohio, 45242
United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
United States
Oregon Health and Science University
Portland, Oregon, 97239
United States
Local Institution - 0070
Philadelphia, Pennsylvania, 19107
United States
Local Institution - 0066
Nashville, Tennessee, 37203
United States
Local Institution - 0043
Nashville, Tennessee, 37232
United States
Local Institution - 0069
Austin, Texas, 78704
United States
Local Institution - 0035
Dallas, Texas, 75390
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States
Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute
San Antonio, Texas, 78229
United States
LDS Hospital
Salt Lake City, Utah, 84143
United States
Virginia Oncology Associates
Norfolk, Virginia, 23502
United States
Fred Hutchinson Cancer Center
Seattle, Washington, 98109
United States
University Hospital and UW Health Clinics
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-21
Study Completion Date2032-06-30

Study Record Updates

Study Start Date2024-03-21
Study Completion Date2032-06-30

Terms related to this study

Keywords Provided by Researchers

  • Relapsed or Refractory Multiple Myeloma
  • Multiple Myeloma
  • BMS-986393
  • CAR T Cell Therapy
  • RRMM
  • Arlocabtagene Autoleucel

Additional Relevant MeSH Terms

  • Multiple Myeloma